These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 12431029)

  • 1. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
    Nitiss JL
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs.
    Potter AJ; Rabinovitch PS
    Mutat Res; 2005 May; 572(1-2):27-44. PubMed ID: 15790488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of topoisomerases as anticancer drugs: problems and prospects.
    Dwarakanath BS; Khaitan D; Mathur R
    Indian J Exp Biol; 2004 Jul; 42(7):649-59. PubMed ID: 15339028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
    Lotito L; Ferri F; Russo A; Capranico G
    Ital J Biochem; 2007 Jun; 56(2):122-9. PubMed ID: 17722653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
    Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance (review).
    Withoff S; De Jong S; De Vries EG; Mulder NH
    Anticancer Res; 1996; 16(4A):1867-80. PubMed ID: 8712715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From DNA damage to G2 arrest: the many roles of topoisomerase II.
    Larsen AK; Escargueil AE; Skladanowski A
    Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
    Pindur U; Lemster T
    Pharmazie; 1998 Feb; 53(2):79-86. PubMed ID: 9540103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase I interactive agents.
    Stewart CF
    Cancer Chemother Biol Response Modif; 2001; 19():85-128. PubMed ID: 11686040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerases in cancer chemotherapy: basic and applied aspects.
    Cortés F; Pastor N
    Cytobios; 2001; 106 Suppl 2():217-27. PubMed ID: 11545448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 6-Arylamino-7-chloro-quinazoline-5,8-diones as novel cytotoxic and DNA topoisomerase inhibitory agents.
    Park HJ; Kim YS; Kim JS; Lee EJ; Yi YJ; Hwang HJ; Suh ME; Ryu CK; Lee SK
    Bioorg Med Chem Lett; 2004 Jul; 14(13):3385-8. PubMed ID: 15177438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
    Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
    Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
    Smith PJ
    Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II inhibitors.
    Clapp JM; Hande KR
    Cancer Chemother Biol Response Modif; 2002; 20():125-49. PubMed ID: 12703203
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
    Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, docking, and synthesis of novel indeno[1,2-c]isoquinolines for the development of antitumor agents as topoisomerase I inhibitors.
    Cho WJ; Le QM; My Van HT; Youl Lee K; Kang BY; Lee ES; Lee SK; Kwon Y
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3531-4. PubMed ID: 17498951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [DNA topoisomerase inhibitor].
    Hino M; Niitani H
    Nihon Rinsho; 1993 Dec; 51(12):3291-300. PubMed ID: 8283648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.
    Aisner J; Musanti R; Beers S; Smith S; Locsin S; Rubin EH
    Clin Cancer Res; 2003 Jul; 9(7):2504-9. PubMed ID: 12855624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.